Cargando…
High-Throughput UHPLC-MS to Screen Metabolites in Feces for Gut Metabolic Health
Feces are the product of our diets and have been linked to diseases of the gut, including Chron’s disease and metabolic diseases such as diabetes. For screening metabolites in heterogeneous samples such as feces, it is necessary to use fast and reproducible analytical methods that maximize metabolit...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8950041/ https://www.ncbi.nlm.nih.gov/pubmed/35323654 http://dx.doi.org/10.3390/metabo12030211 |
_version_ | 1784675048710209536 |
---|---|
author | de Zawadzki, Andressa Thiele, Maja Suvitaival, Tommi Wretlind, Asger Kim, Min Ali, Mina Bjerre, Annette F. Stahr, Karin Mattila, Ismo Hansen, Torben Krag, Aleksander Legido-Quigley, Cristina |
author_facet | de Zawadzki, Andressa Thiele, Maja Suvitaival, Tommi Wretlind, Asger Kim, Min Ali, Mina Bjerre, Annette F. Stahr, Karin Mattila, Ismo Hansen, Torben Krag, Aleksander Legido-Quigley, Cristina |
author_sort | de Zawadzki, Andressa |
collection | PubMed |
description | Feces are the product of our diets and have been linked to diseases of the gut, including Chron’s disease and metabolic diseases such as diabetes. For screening metabolites in heterogeneous samples such as feces, it is necessary to use fast and reproducible analytical methods that maximize metabolite detection. As sample preparation is crucial to obtain high quality data in MS-based clinical metabolomics, we developed a novel, efficient and robust method for preparing fecal samples for analysis with a focus in reducing aliquoting and detecting both polar and non-polar metabolites. Fecal samples (n = 475) from patients with alcohol-related liver disease and healthy controls were prepared according to the proposed method and analyzed in an UHPLC-QQQ targeted platform in order to obtain a quantitative profile of compounds that impact liver-gut axis metabolism. MS analyses of the prepared fecal samples have shown reproducibility and coverage of n = 28 metabolites, mostly comprising bile acids and amino acids. We report metabolite-wise relative standard deviation (RSD) in quality control samples, inter-day repeatability, LOD (limit of detection), LOQ (limit of quantification), range of linearity and method recovery. The average concentrations for 135 healthy participants are reported here for clinical applications. Our high-throughput method provides a novel tool for investigating gut-liver axis metabolism in liver-related diseases using a noninvasive collected sample. |
format | Online Article Text |
id | pubmed-8950041 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-89500412022-03-26 High-Throughput UHPLC-MS to Screen Metabolites in Feces for Gut Metabolic Health de Zawadzki, Andressa Thiele, Maja Suvitaival, Tommi Wretlind, Asger Kim, Min Ali, Mina Bjerre, Annette F. Stahr, Karin Mattila, Ismo Hansen, Torben Krag, Aleksander Legido-Quigley, Cristina Metabolites Article Feces are the product of our diets and have been linked to diseases of the gut, including Chron’s disease and metabolic diseases such as diabetes. For screening metabolites in heterogeneous samples such as feces, it is necessary to use fast and reproducible analytical methods that maximize metabolite detection. As sample preparation is crucial to obtain high quality data in MS-based clinical metabolomics, we developed a novel, efficient and robust method for preparing fecal samples for analysis with a focus in reducing aliquoting and detecting both polar and non-polar metabolites. Fecal samples (n = 475) from patients with alcohol-related liver disease and healthy controls were prepared according to the proposed method and analyzed in an UHPLC-QQQ targeted platform in order to obtain a quantitative profile of compounds that impact liver-gut axis metabolism. MS analyses of the prepared fecal samples have shown reproducibility and coverage of n = 28 metabolites, mostly comprising bile acids and amino acids. We report metabolite-wise relative standard deviation (RSD) in quality control samples, inter-day repeatability, LOD (limit of detection), LOQ (limit of quantification), range of linearity and method recovery. The average concentrations for 135 healthy participants are reported here for clinical applications. Our high-throughput method provides a novel tool for investigating gut-liver axis metabolism in liver-related diseases using a noninvasive collected sample. MDPI 2022-02-25 /pmc/articles/PMC8950041/ /pubmed/35323654 http://dx.doi.org/10.3390/metabo12030211 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article de Zawadzki, Andressa Thiele, Maja Suvitaival, Tommi Wretlind, Asger Kim, Min Ali, Mina Bjerre, Annette F. Stahr, Karin Mattila, Ismo Hansen, Torben Krag, Aleksander Legido-Quigley, Cristina High-Throughput UHPLC-MS to Screen Metabolites in Feces for Gut Metabolic Health |
title | High-Throughput UHPLC-MS to Screen Metabolites in Feces for Gut Metabolic Health |
title_full | High-Throughput UHPLC-MS to Screen Metabolites in Feces for Gut Metabolic Health |
title_fullStr | High-Throughput UHPLC-MS to Screen Metabolites in Feces for Gut Metabolic Health |
title_full_unstemmed | High-Throughput UHPLC-MS to Screen Metabolites in Feces for Gut Metabolic Health |
title_short | High-Throughput UHPLC-MS to Screen Metabolites in Feces for Gut Metabolic Health |
title_sort | high-throughput uhplc-ms to screen metabolites in feces for gut metabolic health |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8950041/ https://www.ncbi.nlm.nih.gov/pubmed/35323654 http://dx.doi.org/10.3390/metabo12030211 |
work_keys_str_mv | AT dezawadzkiandressa highthroughputuhplcmstoscreenmetabolitesinfecesforgutmetabolichealth AT thielemaja highthroughputuhplcmstoscreenmetabolitesinfecesforgutmetabolichealth AT suvitaivaltommi highthroughputuhplcmstoscreenmetabolitesinfecesforgutmetabolichealth AT wretlindasger highthroughputuhplcmstoscreenmetabolitesinfecesforgutmetabolichealth AT kimmin highthroughputuhplcmstoscreenmetabolitesinfecesforgutmetabolichealth AT alimina highthroughputuhplcmstoscreenmetabolitesinfecesforgutmetabolichealth AT bjerreannettef highthroughputuhplcmstoscreenmetabolitesinfecesforgutmetabolichealth AT stahrkarin highthroughputuhplcmstoscreenmetabolitesinfecesforgutmetabolichealth AT mattilaismo highthroughputuhplcmstoscreenmetabolitesinfecesforgutmetabolichealth AT hansentorben highthroughputuhplcmstoscreenmetabolitesinfecesforgutmetabolichealth AT kragaleksander highthroughputuhplcmstoscreenmetabolitesinfecesforgutmetabolichealth AT legidoquigleycristina highthroughputuhplcmstoscreenmetabolitesinfecesforgutmetabolichealth |